Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (16590)	2/10/2004 12:50:54 AM
From: aknahow	Read Replies (2) \| Respond to of 17367

Comments? Seems like bad news, short term. Might even shed light on why Serono had to run a trial. I had no idea that there was any concern about use over one year. "Member has not already been received the referenced biological therapy for a duration of 12 months. Efalizumab is considered experimental and investigational for treatment durations of longer than 12 months. According to the FDA approved labeling, the safety and effectiveness of treatment with efalizumab beyond one year have not been established.